Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity

Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity

The high genetic variability of influenza A viruses poses a continual challenge to seasonal and pandemic vaccine development, leaving antiviral drugs as the first line of defense against antigenically different strains or new subtypes. As resistance against drugs targeting viral proteins emerges rap...

Full description

Bibliographic Details
Main Authors: Theresa Enkirch, Svenja Sauber, Danielle E. Anderson, Esther S. Gan, Dimitar Kenanov, Sebastian Maurer-Stroh, Veronika von Messling
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Immunology
Subjects:
influenza A virus
drug repurposing
antiviral (H1N1 and H3N2) activity
animal models
host protein-targeting drugs
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01097/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01097/full

Similar Items